Home > Back to Publisher > Report Information

Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets Report

CHI Insight Pharma Reports
June 1, 2010
168 Pages - SKU: CHI2713877

Abstract Table of Contents Related Reports

Epigenetics is a rapidly growing field with promising implications for treatment of cancer and potentially other diseases. Research interest in epigenetics has exploded in recent years, and considerable progress has been made in the commercialization of discoveries in this field.

Discussed in this Report:

Diagnostic applications of epigenetics
Diseases and conditions targeted by current and emerging epigenetic-based therapies
Companies marketing and/or developing therapies that target epigenetic changes within the disease process
Current and projected markets for epigenetic diagnostic and therapeutic products
Strategic issues and major challenges for developers of epigenetic-based products
Thought-leader interviews

Many companies have recognized the potential benefits of epigenetic-based diagnostic and therapeutic products. Two epigenetic tests for colorectal cancer screening are CE-marked and available in Europe, and a number of epigenetic tests are available through clinical laboratories in the United States as laboratory developed tests (LDTs). Four epigenetic drugs have now been approved by the US FDA.

EXECUTIVE SUMMARY
CHAPTER 1
INTRODUCTION: Scope and Organization of the Report
CHAPTER 2
OVERVIEW OF EPIGENETICS: 2.1. Definition of Epigenetics; 2.2. Mechanisms of Epigenetics; 2.3. Methods to Detect Differences in DNA Methylation; 2.4. Targets for Current and Emerging Epigenetic Drugs
CHAPTER 3
DIAGNOSTIC COMPANIES IN EPIGENETICS: 3.1. Companies Developing Epigenetic-Based Diagnostic Tests; 3.2. Clinical Laboratories Offering Tests to Detect DNA Methylation Changes; 3.3. Epigenetics/DNA Methylation Test Agreements
CHAPTER 4
MAJOR DISEASES/CONDITIONS TARGETED BY NEW AND/OR EMERGING EPIGENETIC DRUGS: 4.1. Hematological Cancers; 4.2. Solid Tumors; 4.3. Other Emerging Disease Indications
CHAPTER 5
EPIGENETIC DRUGS ON THE MARKET AND IN DEVELOPMENT: 5.1. Drugs Targeting DNA Methylation (DNA Hypomethylation Drugs); 5.2. HDAC Inhibitors; 5.3. Emerging Therapies Directed Against Other Epigenetic Targets
CHAPTER 6
BUSINESS CONSIDERATIONS IN EPIGENETICS: 6.1. Epigenetics Markets; 6.2. Major Challenges/Hurdles and Strategic Issues for Diagnostic Companies in Epigenetics; 6.3. Major Challenges/Hurdles and Strategic Issues for Therapeutic Companies in Epigenetics; 6.4. Evaluating DNA Methylation Markers for Non-Epigenetic Cancer Therapies; 6.5. Evolution of Companies in Epigenetics
CHAPTER 7: EXPERT INTERVIEWS; 7.1. Walter C. Ogier, President and Chief Executive Officer, Acetylon Pharmaceuticals; 7.2. Nessa Carey, PhD, Scientific Director, CellCentric; 7.3. Alan Drummond, PhD, Chief Scientific Officer, Chroma Therapeutics; 7.4. Mark A. Goldsmith, MD, PhD, President and Chief Executive Officer, Constellation Pharmaceuticals; 7.5. Kees Been, President and Chief Executive Officer; Dana Hilt, MD, Senior Vice President, Clinical Development and Chief Medical Officer, EnVivo Pharmaceuticals; 7.6. Oliver Schacht, PhD, CFO, Epigenomics AG, CEO, Epigenomics Inc.; 7.7. Robert Gould, PhD, President and Chief Executive Officer, Epizyme; 7.8. Jeffrey M. Besterman, PhD, Executive Vice President, Research & Development and Chief Scientific Officer, MethylGene; 7.9. Harry Schrickx, WW Vice President Business Development, OncoMethylome Sciences SA, President, OncoMethylome Sciences, Inc.; 7.10. Kamran Tahamtanzadeh, Founder & CEO, PrognosDx Health; 7.11. James R. Rusche, PhD, Senior Vice President, Research and Development, Repligen; 7.12. Joanna Horobin, MD, President & Chief Executive Officer, Syndax Pharmaceuticals; 7.13. Henri Lichenstein, PhD, Chief Development Officer, TopoTarget A/S
REFERENCES
COMPANY INDEX WITH WEB ADDRESSES
FIGURES: Figure 1.1. Number of Abstracts Per Year from PubMed Search for “epigenetic OR epigenetics OR epigenomic OR epigenomics”; Figure 2.1. The Epigenetic Pathway; Figure 2.2. The Increasing Structural Complexity of Genetic Information from the Double-Helical Structure of DNA, through Nucleosome and Chromatin Structures, to the Chromosome; Figure 2.3. Schematic of the Nucleosome Showing Types of Post-Translational Modifications That Can Occur and the Enzymes Responsible for Them; Figure 2.4. Proposed Mechanism of Action of DNA Methylation Inhibitors in Cancer Therapy
TABLES: Table 2.1. Methods Available to Analyze DNA Methylation; Table 3.1. Companies Developing and/or Offering Epigenetic-Based Diagnostic Tests; Table 3.2. Clinical Laboratories Developing and/or Offering Epigenetic-Based Diagnostic Tests for Cancer; Table 3.3. Epigenetic Agreements; Table 4.1. Incidence of Hematological Cancers in the United States; Table 4.2. Incidence of Selected Cancers (Solid Tumors) in the United States (2009); Table 5.1. Companies Marketing and Developing DNA Methylation Inhibitors; Table 5.2. Companies Marketing and Developing HDAC Inhibitors; Table 5.3. Companies Developing Novel Therapies Targeting Sirtuins; Table 5.4. Companies Developing Other Emerging Epigenetic Therapies; Table 6.1. Reported 2009 Sales of Approved Epigenetic Drugs; Table 6.2. Selected Epigenetic Therapeutic Agreements; Table 6.3. Selected Companies That Have Out-Licensed Epigenetic Drug Technology/Compounds and No Longer Appear to be Active in the Epigenetics Field

Epigenetic Drug & Diagnostic Pipelines: DNA Methylation, HDAC Inhibitors, and Emerging New Targets Report

Share this report

Other tasks

Research Assistance

Related Markets

Emerging Technology Reports

Free Alert Me service